MedTrace Logo

Emotion, Mood and Executive Function in Parkinson's Disease (PD)

NCT01385735 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2011-06-30

No results posted yet for this study

Summary

The current study aims to assess the effect of an 8 week Azilect treatment (as adjunct therapy to levodopa) on affect perception and emotional expressiveness in a double-blind placebo-controlled study.

Conditions

  • Parkinson Disease

Interventions

DRUG

Rasagiline

Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration

DRUG

Placebo

Placebo 1 Tbl per day, 12 week (84 days) duration

Sponsors & Collaborators

  • St. Josef Hospital Bochum

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-10-31
Completion
2013-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01385735 on ClinicalTrials.gov